News Quantified

ADXS – advaxis, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Form 10-K/A Ayala Pharmaceuticals, For: Dec 31

Form 8-K/A Ayala Pharmaceuticals, For: Mar 25

Form 10-K Ayala Pharmaceuticals, For: Dec 31

Form S-8 POS Ayala Pharmaceuticals,

Form S-8 POS Ayala Pharmaceuticals,

Top News Gainers

1/30 Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings 38.7%

3/16 Form 4 Advaxis, Inc. For: Mar 11 Filed by: APPEL RONI 18.3%

4/4 Coronavirus Roundtable - Strains And Hopes In The Healthcare Sector [Seeking Alpha] 17.2%

10/4 Form 8-K Advaxis, Inc. For: Oct 04 15.1%

2/28 Form 10-K/A Advaxis, Inc. For: Oct 31 9.8%

6/4 Advaxis to Host Business Update Conference Call on June 11, 2019 8.2%

1/16 Form 8-K Advaxis, Inc. For: Jan 16 7.6%

2/27 Form 8-K Advaxis, Inc. For: Feb 27 7.5%

7/17 Form FWP Advaxis, Inc. Filed by: Advaxis, Inc. 7.1%

2/14 Form SC 13G/A Advaxis, Inc. Filed by: Anson Funds Management LP 4.0%

Top News Decliners

7/22 Advaxis, Inc. (NASDAQ: ADXS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -26.1%

7/22 Form S-1/A Advaxis, Inc. -22.5%

7/2 Form S-1 Advaxis, Inc. -19.5%

7/31 Form 8-K Advaxis, Inc. For: Jul 31 -16.2%

2/27 Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference -13.4%

7/24 Form 424B4 Advaxis, Inc. -12.4%

3/13 Q1/2020 1/31/2020 EPS -0.150 ZacksConsensus N/A ActVsEst N/A - N/A -12.4%

2/13 Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium -11.9%

9/9 Q3/2019 7/31/2019 EPS -1.000 ZacksConsensus -1.240 ActVsEst 0.240 - Beat -11.8%

2/20 Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting -11.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day